SCHEMBL4480210

SCHEMBL4480210

O=C(Nc1ccn(Cc2cccc(F)c2)c(=O)c1Br)c1ccc(F)cc1F

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MEN1 O00255 1/20 0.56
HTT P42858 1/20 0.56
KMT2A Q03164 1/20 0.56
MAPK14 Q16539 4/20 0.54
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TP53 P04637 2/20 0.47
PTGER3 P43115 1/20 0.46
MET P08581 1/20 0.45
AXL P30530 1/20 0.45
FSCN1 Q16658 1/20 0.44
HSD17B13 Q7Z5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467899 0.92 MAPT (0.54) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4378804 0.87 MAPK14 (0.56) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4385079 0.87 MAPK14 (0.51) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4476536 0.86 MAPK14 (0.55) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4466743 0.82 MAPK14 (0.60) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL3521684 0.82 MAPT (0.48) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4376114 0.79 MAPK14 (0.64) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4474073 0.78 MAPK14 (0.57) L3MBTL1SMN1; SMN2MEN1KMT2AMAPK14
SCHEMBL4478413 0.77 MAPK14 (0.56) MAPTL3MBTL1SMN1; SMN2MEN1HTT
SCHEMBL4389631 0.76 ALDH1A1 (0.55) L3MBTL1SMN1; SMN2MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPT 2803/4885L3MBTL1 3937/4885SMN1; SMN2 1433/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPT 2543/4885L3MBTL1 3850/4885SMN1; SMN2 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.